Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Recruiting · NCT04061421 · Registry updated 2026-04-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) | myelodysplastic/myeloproliferative neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-21 | NCT04061421 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astex Pharmaceuticals, Inc. | 12 |
| Incyte Corporation | 153 |
| Michael Savona | 1 |
| Theradex | 4 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Moffitt Cancer Center | Tampa | United States | 523 |
| Oregon Health Sciences University | Portland | United States | 33 |
| University of Rochester Wilmot Cancer Institute | Rochester | United States | 1 |
| Vanderbilt-Ingram Cancer Center | Nashville | United States | 48 |